Your session is about to expire
← Back to Search
Triapine + Targeted Radiation for Neuroendocrine Cancer
Study Summary
This trial compares the effect of adding a drug to a radioactive medication to shrink or slow tumor growth in metastatic neuroendocrine tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am allergic to medications similar to triapine or lutetium Lu 177 dotatate.I have recovered from side effects of my previous treatments.I have recovered from side effects of past treatments, except for hair loss.I can take care of myself but may not be able to do heavy physical work.I have tried a somatostatin analog treatment for my cancer without success.I am not pregnant or breastfeeding.I will avoid pregnancy or fathering a child for 7 months after my last treatment.My cancer has grown despite treatment, confirmed by scans in the last 24 months.My heart condition is not under control and severely limits my daily activities.I have never had peptide receptor radionuclide therapy.My brain scans show no cancer growth 4 weeks after treatment, and I'm not on steroids.I have another cancer, but it won't affect this trial's treatment.My heart function is classified as class 2B or better according to the NYHA.My hepatitis B virus load is undetectable with treatment.I had hepatitis C but am cured, or I'm being treated with no detectable virus.I am 18 years old or older.I have a specific type of cancer that has spread and shows up on certain scans, but it's not in my lungs.I am HIV positive, on treatment, and my viral load is undetectable.I cannot swallow pills or have a gut condition affecting medication absorption.My kidney function, measured by creatinine levels, is within the normal range or slightly above.
- Group 1: Arm 1 (triapine, lutetium Lu 177 dotatate)
- Group 2: Arm 2 (lutetium Lu 177 dotatate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies left in this research project?
"Clinicaltrials.gov reveals that this medical trial is currently open for enrollment, with the initial posting taking place on March 15th 2023 and its most recent update occurring a mere fortnight ago."
What is the current size of this research trial's participant pool?
"That is correct. According to clinicaltrials.gov, this medical trial opened on March 15th of 2021 and was recently updated on the 28th of that same month. Researchers are searching for 94 volunteers from a single site."
Has Group II (lutetium Lu 177 dotatate, triapine) been given the go-ahead by federal regulators?
"Our team at Power has assigned a score of 2 to Group II (lutetium Lu 177 dotatate, triapine) due to the fact that there is some safety data available from Phase 2 trials but no evidence yet demonstrating its efficacy."
Share this study with friends
Copy Link
Messenger